Not everyone is convinced that the new Sanofi CEO will remain committed to MannKind and its inhaled insulin Afrezza.
Briefing documents for Thursday's FDA advisory panel reviewing Rockwell Medical's RMTI Triferic iron replacement therapy were posted to the agency's web site this morning.
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The accusations of cocaine use and having sex with someone else's wife are the least of Marc Beer's problems. Aegerion Pharmaceuticals, the company he runs as CEO, is falling apart.
Aegerion Pharmaceuticals issued a statement Tuesday night expressing its board's support for CEO Marc Beer in the face of accusations of cocaine use and extramarital sex.
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
A dirty divorce for one of Wall Street's top bankers just got messier.
FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.
Both CEOs deny allegations in an ugly divorce case that they snorted cocaine with a Jefferies & Co. health care investment banker.